Cyrus Harmon - 28 Jun 2024 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: Director
Issuer ticker: OLMA
Reported as of: 28 Jun 2024
Net transaction value: -$215,400
SEC form: 4
Accepted by SEC: 02 Jul 2024, 17:30:28 UTC
Prior SEC filing: 18 Jun 2024
Next SEC filing: 12 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Shane Kovacs, Attorney-in-Fact

Key filing fact

Cyrus Harmon filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 02 Jul 2024.

Key facts

This page summarizes Cyrus Harmon's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jul 2024, 17:30.

Change

Previous filing in this sequence was filed on 18 Jun 2024.
Current net transaction value: -$215,400.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OLMA transaction

Common Stock

Sale

Transaction value: $215,400
Shares: -20,000
Change %: -2.6%
Price: $10.77
Shares after: 761,283
Date: 28 Jun 2024
Ownership: Direct
Footnotes: F1, F2

OLMA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 122,028
Date: 28 Jun 2024
Ownership: See Footnote
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person dated May 16, 2023.

Footnote F2

The weighted average sale price for the transaction reported was $10.77, and the range of prices was between $10.55 and $11.21. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

Footnote F3

The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.